MX2023006567A - Regimen de dosificacion para un nam del receptor nr2b-nmda para el tratamiento de la depresion. - Google Patents
Regimen de dosificacion para un nam del receptor nr2b-nmda para el tratamiento de la depresion.Info
- Publication number
- MX2023006567A MX2023006567A MX2023006567A MX2023006567A MX2023006567A MX 2023006567 A MX2023006567 A MX 2023006567A MX 2023006567 A MX2023006567 A MX 2023006567A MX 2023006567 A MX2023006567 A MX 2023006567A MX 2023006567 A MX2023006567 A MX 2023006567A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- nr2b
- dosage regimen
- nmda receptor
- depression
- Prior art date
Links
- 108010054200 NR2B NMDA receptor Proteins 0.000 title abstract 2
- 208000020401 Depressive disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024714 major depressive disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010042458 Suicidal ideation Diseases 0.000 abstract 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121508P | 2020-12-04 | 2020-12-04 | |
| US202063121513P | 2020-12-04 | 2020-12-04 | |
| PCT/IB2021/061268 WO2022118264A1 (en) | 2020-12-04 | 2021-12-03 | Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006567A true MX2023006567A (es) | 2023-06-16 |
Family
ID=78844691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006567A MX2023006567A (es) | 2020-12-04 | 2021-12-03 | Regimen de dosificacion para un nam del receptor nr2b-nmda para el tratamiento de la depresion. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240041853A1 (enExample) |
| EP (1) | EP4255419A1 (enExample) |
| JP (1) | JP2023551943A (enExample) |
| KR (1) | KR20230116865A (enExample) |
| AU (1) | AU2021390209A1 (enExample) |
| CA (1) | CA3203144A1 (enExample) |
| IL (1) | IL303357A (enExample) |
| MX (1) | MX2023006567A (enExample) |
| TW (1) | TW202237103A (enExample) |
| WO (1) | WO2022118264A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119654149A (zh) * | 2022-06-02 | 2025-03-18 | 诺华股份有限公司 | 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法 |
| WO2025120013A1 (en) * | 2023-12-06 | 2025-06-12 | Novartis Ag | Compositions and methods for treating depression disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| US9540324B2 (en) * | 2013-09-26 | 2017-01-10 | Luc Therapeutics, Inc. | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B |
| JO3579B1 (ar) * | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| CA2970958A1 (en) * | 2014-12-23 | 2016-06-30 | Cerecor, Inc. | Compounds, compositions and methods |
| MX2018004256A (es) * | 2015-10-14 | 2018-05-16 | Squibb Bristol Myers Co | Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. |
| CA3001894A1 (en) * | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
-
2021
- 2021-12-03 EP EP21824044.8A patent/EP4255419A1/en not_active Withdrawn
- 2021-12-03 AU AU2021390209A patent/AU2021390209A1/en not_active Abandoned
- 2021-12-03 KR KR1020237021993A patent/KR20230116865A/ko active Pending
- 2021-12-03 MX MX2023006567A patent/MX2023006567A/es unknown
- 2021-12-03 US US18/255,423 patent/US20240041853A1/en not_active Abandoned
- 2021-12-03 JP JP2023533801A patent/JP2023551943A/ja active Pending
- 2021-12-03 CA CA3203144A patent/CA3203144A1/en active Pending
- 2021-12-03 TW TW110145295A patent/TW202237103A/zh unknown
- 2021-12-03 IL IL303357A patent/IL303357A/en unknown
- 2021-12-03 WO PCT/IB2021/061268 patent/WO2022118264A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021390209A1 (en) | 2023-06-22 |
| KR20230116865A (ko) | 2023-08-04 |
| WO2022118264A1 (en) | 2022-06-09 |
| CA3203144A1 (en) | 2022-06-09 |
| US20240041853A1 (en) | 2024-02-08 |
| AU2021390209A9 (en) | 2024-10-31 |
| IL303357A (en) | 2023-08-01 |
| JP2023551943A (ja) | 2023-12-13 |
| EP4255419A1 (en) | 2023-10-11 |
| TW202237103A (zh) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20240210A1 (ar) | مثبطات kras | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| MX2021002321A (es) | Nuevos metodos. | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| JO3707B1 (ar) | مركبات كينازولين مستبدلة وطرق استعمالها | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2021005992A (es) | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| BR112016020381A8 (pt) | sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina. | |
| EA202091841A1 (ru) | Осимертиниб для применения для лечения немелкоклеточного рака легкого | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| MX2022003134A (es) | Administracion intranasal de esketamina. | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| MX2022007911A (es) | Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7. | |
| MX350195B (es) | Analogos de cistamina para el tratamiento de la enfermedad de parkinson. | |
| BR112019002461A2 (pt) | regime de dosagem para tratamento de tumores sólidos | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| MX2024014906A (es) | Administracion subcutanea de onfasprodil y métodos de dosificación para su itilizacion en el tratamiento de trastornos depresivos | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. |